Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419666 · ClinicalTrials.gov registry record · Phase 2
A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00419666 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 25 participants.
The verdict
NCT00419666, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA involved, excluding face, scalp and intertriginous areas) for 56 days (8 weeks). Full Pharmacokinetic (PK) and Pharmacodynamic (PD) profile will be collected during the first 3 weeks of the study; safety and efficacy data will be collected for the 8 weeks of the treatment.
Interventions
- DRUG Calcitriol 3mcg/g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-08-01 |
| Est. Completion | 2009-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419666
The ClinicalTrials.gov registry entry for NCT00419666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calcitriol 3mcg/g is the first listed.
NCT00419666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419666 about?
NCT00419666 is a clinical study titled "A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis". This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA involved, excluding face, scalp and intertriginous areas) for 56 days ...
What is the current status of trial NCT00419666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-08-01. Estimated completion is 2009-09-24.
What interventions are being tested in trial NCT00419666?
The interventions under investigation include: Calcitriol 3mcg/g (DRUG).
Who is sponsoring clinical trial NCT00419666?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.